The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver

被引：6

作者：

Geva, Ravit ^{[1
]}

Shamai, Sivan ^{[1
]}

Brazowsky, Eli ^{[2
]}

Paoulas, Michael ^{[2
,3
]}

Ben-Haim, Mendi ^{[2
,3
]}

Johnstone, Elaine ^{[7
]}

Alex, Beny ^{[4
,5
,6
]}

Shacham-Shmueli, Einat ^{[1
]}

机构：

[1] Tel Aviv Sourasky Med Ctr, Div Oncol, Gastrointestinal Malignancies Serv, IL-6423906 Tel Aviv, Israel

[2] Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-6423906 Tel Aviv, Israel

[3] Tel Aviv Sourasky Med Ctr, Div Surg, IL-6423906 Tel Aviv, Israel

[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel

[5] Rambam Med Ctr, Div Oncol, Haifa, Israel

[6] Technion Israel Inst Technol, Haifa, Israel

[7] Univ Oxford, Dept Oncol, Oxford OX1 2JD, England

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 04期

关键词：

Metastatic colorectal cancer; ERCC1; Oxaliplatin; PREOPERATIVE CHEMOTHERAPY; THYMIDYLATE SYNTHASE; GENE-EXPRESSION; RESECTION; SURVIVAL; SURGERY; STEATOHEPATITIS; 5-FLUOROURACIL; INCREASE;

D O I：

10.3109/07357907.2014.998834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Increased expression of excision repair cross-complementing 1 (ERCC1) inmCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgicalmargins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.

引用

页码：89 / 97

页数：9

共 50 条

[41] PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
Papadaki, C.
Saridaki, Z.
Tzardi, M.
Sfakianaki, M.
Sfakiotaki, G.
Trypaki, M.
Messaritakis, I.
Mavroudis, D.
Georgoulias, V.
Sougklakos, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[42] Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin, and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients
Hernandez, A.
Bandres, E.
Rodriguez, J.
Bitarte, N.
Ramirez, N.
Zarate, R.
Abajo, A.
Chopitea, A.
Viudez, A.
Garcia-Foncillas, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[43] ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
Zhao-Hui Huang
World Journal of Gastroenterology, 2008, (41) : 6401 - 6407
[44] ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
Huang, Zhao-Hui
Hua, Dong
Du, Xiang
Li, Li-Hua
Mao, Yong
Liu, Zhi-Hui
Song, Ming-Xu
Zhou, Xi-Ke
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (41) : 6401 - 6407
[45] Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients
Bandres, E.
Rodriguez, J.
Hernandez, A.
Bitarte, N.
Ramirez, N.
Diaz-Gonzalez, J. A.
Chopitea, A.
Ponz, M.
Zarate, R. N.
Garcia-Foncillas, J.
EJC SUPPLEMENTS, 2009, 7 (02): : 113 - 113
[46] Population-based patterns of systemic therapy use in liver-limited metastatic colorectal cancer (mCRC)
Kellock, Trenton Tyler
Gresham, Gillian
Cheung, Winson Y.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[47] KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
M Basso
A Strippoli
A Orlandi
M Martini
M A Calegari
G Schinzari
M Di Salvatore
T Cenci
A Cassano
L M Larocca
C Barone
British Journal of Cancer, 2013, 108 : 115 - 120
[48] KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
Basso, M.
Strippoli, A.
Orlandi, A.
Martini, M.
Calegari, M. A.
Schinzari, G.
Di Salvatore, M.
Cenci, T.
Cassano, A.
Larocca, L. M.
Barone, C.
BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 115 - 120
[49] Use of ERCC1 gene expression to predict the effectiveness of platin-based therapy in colorectal, ovarian and lung cancer
Omori, A.
Hoffmann, A. C.
Shi, M. M.
Lenz, H. J.
Michie, C. O.
Gourley, C. M.
Cooc, J.
Clark, J. S.
Danenberg, K. D.
Danenberg, P. V.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[50] Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients
Li, Pan
Xiao, Zhi-Tao
Braciak, Todd A.
Ou, Qing-Jian
Chen, Gong
Oduncu, Fuat S.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (11) : 702 - 706

← 1 2 3 4 5 →